Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 20, No 11 (2022) > Article

DOI: 10.14704/nq.2022.20.11.NQ66067

EFFICACY AND SAFETY OF TARGETED THERAPY IN PATIENTS WITH PSORIASIS

AkramBaratovichRakhmatov, NaziraAnvarovnaRasulova

Abstract

The pathogenesis of psoriasis is largely associated with the cytokine system (expression of proinflammatory cytokines), which served as the basis for the development of special biological drugs that are the basis of targeted therapy of this dermatosis. The predominant role of individual cytokines, in particular IL-17, in the development of psoriatic arthritis has been proven. In the treatment of 72 patients with psoriasis (vulgar and arthropathic forms of dermatosis), a selective IL-17 inhibitor, a biological drug "SCAFO" (secukinumab), was used, which in most cases allowed not only to cause regression of psoriatic rashes with long-term remission of the disease, but also significantly improve the CASPAR criteria, reflecting the clinical manifestations of osteoarticular syndrome in patients with psoriasis.

Keywords

psoriasis, diagnosis, joint syndrome, treatment, biological drugs.

Full Text

PDF

References

?>